AGN

3 Stocks to Watch on Tuesday: A Schulman Inc, Allergan plc and Urban Outfitters, Inc.

By Karl Utermohlen, InvestorPlace Writer
A Schulman (SHLM) updated its guidance, Allergan (AGN) unveils revenue expectations and Urban Outfitters (URBN) comps rise 2% during holidays.

Allergan plc (AGN) Layoffs: Company Plans 1,000+ Job Cuts

By Karl Utermohlen, InvestorPlace Writer
Pharmaceutical Allergan (AGN) announced that it will cut over 1,000 jobs in a bid to reduce costs as part of a broader restructuring effort.

10 More Losers That Will Be Stocks to Buy in 2018

By Vince Martin, InvestorPlace Contributor
These 10 stocks have seen their values decline so far in 2017. But all 10 have good reason to see improvement in 2018 -- and possibly beyond.

Allergan (AGN) a Sell on Sinking Industry Group Rank

By Portfolio Grader
Allergan Inc (NYSE:AGN) is ranked as a Sell using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. This represents no change from the previous week and is the same ranking AGN has had from Portfolio Grader for 4 months.

Buy Allergan Plc Ordinary Shares After the Earnings!

By Nicolas Chahine, InvestorPlace Contributor
After a long stint of selling, AGN stock is finally showing signs of stabilization. I want to generate income from Allergan support.

4 Biotech Stocks (and 1 ETF) to Buy As They Bolt Higher

By Anthony Mirhaydari, InvestorPlace Market Strategist
These biotech stocks are making a comeback amid several positive catalysts for the sector and markets as a whole.

Buy Allergan plc Ordinary Shares (AGN) Stock and Don’t Look Back!

By Nicolas Chahine, InvestorPlace Contributor
Pharma stocks like Allergan scare most investors out of trading them when they fall. Sell AGN puts with a big buffer for easy profits.

Allergan plc Ordinary Shares (AGN) May Have Just Saved Itself Billions

By Lawrence Meyers, InvestorPlace Contributor
A clever maneuver by Allergan (AGN) may protect patents from unfair challenges. Here's what biopharma investors need to know.

Battered Teva Pharmaceutical Industries Ltd (ADR) Stock Still Is Toxic

By Bret Kenwell, InvestorPlace Contributor
Teva Pharmaceutical is waist-deep in debt and just slashed its dividend. TEVA stock might be oversold and undervalued, but it's also still a mess.

Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Is Not a Falling Knife, It’s a Guillotine

By Nicolas Chahine, InvestorPlace Contributor
TEVA looks less like a falling knife than like a full-blown guillotine. Still, I will stick my neck in it for a peek at Teva.

2 Red Hot Tech Funds Paying Up to 7.1%: 1 Buy and 1 Sell

By
Everyone is obsessing over FAAMG stocks, but today I'll highlight two funds that invest in these companies while offering higher dividends

7 Healthcare Stocks to Buy Now

By Ryan Fuhrmann, InvestorPlace Contributor
With many healthcare stocks currently trading at attractive discounts, these 7 companies are smart stocks to buy now.

Valeant Pharmaceuticals Intl Inc (VRX) Stock Isn’t Healed by Paulson’s Presence

By James Brumley, InvestorPlace Feature Writer
Valeant Pharmaceuticals (VRX) finds relief as John Paulson joins the board, but what can he really do to help VRX stock holders?

Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Nibble on Its Dividend and Wait

By Ryan Fuhrmann, InvestorPlace Contributor
Teva Pharmaceutical (TEVA) is perhaps the poster child for what can go wrong with an investment. But TEVA stock is cheap and could double in price.

How Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Could Recover

By Vince Martin, InvestorPlace Contributor
Teva Pharmaceutical desperately needs a new CEO - and a new strategy to boot - to stop the steady decline in TEVA stock.

3 Big Stock Charts for Thursday: Allergan plc Ordinary Shares (AGN), Cummins Inc. (CMI) and Michaels Companies Inc (MIK)

By Johnson Research Group
Allergan (AGN), Michaels (MIK) and Cummins (CMI) stock are ready to bounce higher with help from their bullish charts.

Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Can Bounce Now

By Vince Martin, InvestorPlace Contributor
Teva Pharmaceutical's first-quarter earnings and reaffirmed guidance are good enough, and should at least drive a relief rally in TEVA stock.

Vanguard Sector Funds

By Kent Thune, InvestorPlace Contributor
These four low-cost Vanguard sector funds can be smart choices to strengthen your portfolio with tactical exposure.

Valeant Pharmaceuticals Tanks on Ackman Exit Reports (VRX)

By Robert Martin, InvestorPlace Writer
Bill Ackman's two-year relationship with Valeant Pharmaceuticals (VRX) reportedly is at an end, with the activist exiting VRX stock Monday.
Load More